The Power of Particle Characterization - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Power of Particle Characterization
Pharma's drive for manufacturing efficiency is bolstering particle-characterization technologies.


Pharmaceutical Technology
Volume 35, Issue 7, pp. 42-43

Particle-characterization data is central to the development, manufacture, and quality control of pharmaceutical products. The characteristics of a pharmaceutical's composite particles can affect the product in many ways, including by influencing drug efficacy and stability, as well as how the product behaves during processing. When considering the importance of particle characterization, the International Conference on Harmonization's (ICH) Q6A guideline on specifications (1) is a useful starting point because it identifies potentially important particle variables, including polymorphic form, enantiomeric purity, and particle size and distribution. The guideline also provides a decision tree to help determine when related testing is required.


IMAGE: INFLUX PRODUCTIONS, PHOTODISK, GETTY IMAGES
Historically, industry has paid greater attention to control of particle size and distribution, which, according to ICH Q6A, can significantly affect the dissolution rates, bioavailability, and stability of drug substances in both solid and suspension products. Today, particle characteristics are attracting even greater focus as industry strives to increase manufacturing efficiencies. This drive has been largely influenced by the growing emphasis on quality by design (QbD), which encourages pharmaceutical companies to use an information- and risk-based approach to optimize product development and manufacture. Using particle characterization to understand how a product behaves during processing supports this initiative.

This article takes a brief look at what factors have driven innovations in particle-characterization techniques and how technology may advance in this area in the coming years.

Innovations in particle characterization

Two of the earliest particle-sizing techniques were manual microscopy and sieving. These methods are still used today, but both have drawbacks. For instance, microscopy is slow and manually intensive, while sieving is unsuitable for fine or cohesive materials. As such, industry has sought more advanced particle-sizing techniques.

One such approach that is gaining popularity is laser diffraction. "Although laser diffraction methods have been used for the last 30 years, continuous development has resulted in much more accurate and reproducible measurements between manufacturers," explains Graham Rideal, founder of and a senior scientist at Whitehouse Scientific, which specializes in particle-sizing methods.

Paul Kippax, product group manager at Malvern Instruments, a producer of analytical equipment, agrees that laser diffraction is an important technology, particularly because its measurement range (0.1 to 3000 μ) covers the vast majority of particle-sizing applications used by industry. In addition, laser diffraction is capable of high-speed size distribution sampling (typically less than 20 s, according to Kippax), is nondestructive, and is suitable for automation. "Today's laboratory laser diffraction analyzers have been automated to the point of push-button operation, with sample loading being the only remaining routine manual task," says Kippax.

Imaging and microscopy are not being left behind, however. Some recent advances have been made with these analytical techniques. "The continuous and concomitant development of imaging technology and high-speed computers has transformed the humble microscope from a predominantly qualitative instrument into one of the most potent quantitative tools available today," explains Rideal. "This development has extended the definition of a particle from that of a simple equivalent spherical diameter into a comprehensive shape analysis where length, width, and perimeter can be measured at tremendous speeds."


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here